Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133226 | 1.00 | P2RX7 (0.45) | P2RX7KMT2AMEN1EHMT2ALDH1A1 | |
| SCHEMBL12018713 | 0.85 | P2RX7 (0.46) | P2RX7KMT2AMEN1EHMT2ALDH1A1 | |
| SCHEMBL12495007 | 0.85 | P2RX7 (0.47) | P2RX7KMT2AMEN1EHMT2ALDH1A1 | |
| SCHEMBL10215486 | 0.85 | P2RX7 (0.47) | P2RX7KMT2AMEN1EHMT2ALDH1A1 | |
| SCHEMBL6132818 | 0.85 | P2RX7 (0.43) | P2RX7KMT2AMEN1EHMT2HCRTR1 | |
| SCHEMBL1189963 | 0.82 | P2RX7 (0.46) | P2RX7KMT2AMEN1EHMT2HCRTR1 | |
| SCHEMBL1008150 | 0.82 | P2RX7 (0.46) | P2RX7KMT2AMEN1EHMT2HCRTR1 | |
| SCHEMBL1008151 | 0.82 | P2RX7 (0.46) | P2RX7KMT2AMEN1EHMT2HCRTR1 | |
| SCHEMBL21538635 | 0.81 | ALDH1A1 (0.50) | KMT2AMEN1EHMT2ALDH1A1GAA | |
| SCHEMBL20637914 | 0.81 | P2RX7 (0.44) | P2RX7KMT2AMEN1EHMT2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | P2RX7 207/4885KMT2A 3755/4885MEN1 344/4885 |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | P2RX7 124/4885KMT2A 829/4885MEN1 1830/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | P2RX7 290/4885KMT2A 1097/4885MEN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.